Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK starts phase 1 study of IONIS-HBV-LRx to treat hepatitis B virus
The drug is being developed by Ionis Pharmaceuticals and GSK. The companies are also collaborating on the development of IONIS-HBV Rx, a generation 2.0+ antisense HBV drug. Ionis
The drug is being developed by Ionis Pharmaceuticals and GSK. The companies are also collaborating on the development of IONIS-HBV Rx, a generation 2.0+ antisense HBV drug. Ionis
VAL-083 is a small-molecule chemotherapeutic, which is indicated to treat glioblastoma multiforme (GBM), the most common and deadly cancer that starts within the brain. Under the collaboration, MD
The companies will partner in a phase 2 study to evaluate the safety and efficacy of the combination of BioLineRx’s BL-8040 CXCR4 antagonist and Merck’s Keytruda humanized monoclonal
TAF is a novel, once-daily, targeted prodrug of tenofovir that showed high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir
The US Food and Drug Administration (FDA) has granted priority review for venetoclax to treat CLL in adults who have received at least one prior therapy, including patients
The drug maker will work with Moderna Therapeutics to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The partnership
The transaction, which is expected to be completed mid-2016, will create a global biotechnology firm focused on rare diseases. The combined company will provide a foundation for hematology
The first four investments under the company’s new focus have gone to BioAlta, NextCure, Cortexyme and 4D Molecular Therapeutcs. The move will allow the recipients to fully explore
Under the risk-sharing agreement, PPD will assist Moderna in its clinical development efforts, including support for investigational new drug strategic planning, as well as for clinical trial design
Under a research collaboration and licensing agreement, the companies will work together to generate and evaluate up to two bispecific NK cell engagers using Innate Pharma’s technology and